Related Experiment Video

Updated: Jul 13, 2026

A Novel High-Throughput Ex Vivo Ovine Skin Wound Model for Testing Emerging Antibiotics
08:30

A Novel High-Throughput Ex Vivo Ovine Skin Wound Model for Testing Emerging Antibiotics

Published on: September 16, 2022

In vivo activity of a novel polymeric guanidine in experimental skin infection with methicillin-resistant

Christina Kratzer1, Selma Tobudic, Karin Macfelda

  • 1Department of Internal Medicine I, Division of Infectious Diseases and Chemotherapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.

Antimicrobial Agents and Chemotherapy
|July 11, 2007
PubMed

Insights

The novel polymeric guanidine AKACID Plus shows effectiveness against methicillin-resistant Staphylococcus aureus (MRSA) skin infections. Topical AKACID Plus at 0.5% concentration matched mupirocin 2% cream efficacy in a guinea pig model.

Area of Science:

  • Microbiology
  • Dermatology
  • Pharmacology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) is a significant pathogen causing skin infections.
  • Novel antimicrobial agents are needed to combat MRSA.
  • Polymeric guanidines represent a promising class of antimicrobials.

Purpose of the Study:

  • To evaluate the in vivo efficacy of AKACID Plus against MRSA skin infections.
  • To compare AKACID Plus with a standard treatment (mupirocin).

Main Methods:

  • An experimental skin infection model in guinea pigs was utilized.
  • Infections were established using methicillin-resistant Staphylococcus aureus (MRSA).
  • Topical application of AKACID Plus at varying concentrations and mupirocin 2% cream was administered.

Main Results:

  • Topical AKACID Plus at concentrations of 0.5% and higher demonstrated significant efficacy.
  • AKACID Plus efficacy was comparable to 2% mupirocin cream.
  • The study confirmed the in vivo effectiveness of AKACID Plus in treating MRSA skin infections.

Conclusions:

  • AKACID Plus is a potent topical antimicrobial agent against MRSA.
  • This novel polymeric guanidine offers a potential alternative for MRSA skin infection treatment.

More Related Videos

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)

Published on: February 9, 2011

Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro11:52

Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro

Published on: April 21, 2023

Related Concept Videos

Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...